| [1] | 国家食品药品监督管理局. 关于开展中药注射剂安全性再评价工作的通知[EB/OL]. [2009-08-15].http://app1.sfda.gov.cn/WS01/CL0195/35332.html.
|
| [2] | European Union. Regulation (EU) No 1235/2010 of the European parliament and of the council of 15 [EB/OL].[2010-12-01]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0001:0016:EN:PDF.
|
| [3] | European Union. Directive 2010/84/EU of the European parliament and of the council of 15 December 2010: amending, as regards pharmacovigilance, directive 2001/83/EC on the community code relating to medicinal products for human use[EB/OL].[2010-12-31]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:348:0074:0099:EN:PDF.
|
| [4] | The Commission of the European Communities. Guidelines for good clinical practice (commission directive 2005/28/EC) [EB/OL]. [2005-04-09]. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2005:091:0013:0019:en:PDF.
|
| [5] | International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices[EB/OL]. [2007-08-01]. http://www.pharmacoepi.org/resources/guidelines_08027.cfm.
|
| [6] | Hall G C, Sauer B, Bourke A, et al. Guidelines for good database selection and use in pharmacoepidemiology[J]. Res Pharmacoepidemiol Drug Saf, 2012, 21(1): 1.
|
| [7] | International Epidemiological Association(IEA). Good epidemiological practice guidelines[EB/OL].[ 2010-10-01]. http://ieaweb.org/category/guidelines-2/.
|
| [8] | Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research[J]. Basic Clin Pharmacol & Toxicol, 2010, 106(2): 86.
|
| [9] | Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries[J]. Bio Med J, 2012, 344: d8012.
|
| [10] | Kimland E, Odlind V. Off-label drug use in pediatric patients[J]. Clin Pharmacol Ther, 2012, 91(5): 796.
|
| [11] | Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events[J]. Am J Epidemiol, 1991,133(2), 144.
|
| [12] | Schneeweiss S, Sturmer T, Maclure M. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research[J]. Pharmacoepidemiol Drug Saf, 1997, Suppl 3: S51.
|
| [13] | Wang S, Linkletter C, Maclure M, et al. Future-cases as present controls to adjust for exposure-trend bias in case-only studies[J]. Epidemiol, 2011, 22: 568.
|
| [14] | Weldeselassie Y G, Whitaker H J, Farrington C P. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice[J]. Epidemiol Infect,2011, 139(12): 1805.
|
| [15] | Brookhart M A, Rassen J A, Schneeweiss S. Instrumental variable methods incomparative safety and effectiveness research[J]. Pharmacoepidemiol Drug Saf, 2010, 19(6): 537.
|
| [16] | Bate A, Evans S J W. Quantitative signal detection using spontaneous ADR reporting[J]. Pharmacoepidemiol Drug Saf, 2009, 18(6): 427.
|
| [17] | Eudravigilance Expert Working Group(EV-EWG). Guideline on the use of statistical signal detection methods in the eudravigilance data analysis system[EB/OL]. [2008-12-01].http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdf.
|
| [18] | Rosenbaum P R. Design of observational studies[M].Berlin: Springer, 2010.
|
| [19] | International Committee of Medical Journal Editors (ICJME). Uniform requirements for manuscripts submitted to biomedical journals[EB/OL]. [2010-12-31].http://www.icmje.org/urm_main.html.
|
| [20] | European Medicines Agency. Guidelines on good pharmacovigilance practices[EB/OL]. [2012-10-01]. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp.
|
| [21] | The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on methodological standards in pharmacoepidemiology (Revision 1) [EB/OL]. [2012-06-25]. http://www.ema.europa.eu/ema/index.jsp curl=pages/regulation/document_listing/document_listing_000345.jsp.
|
| [22] | The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). ENCePP checklist for study protocols[EB/OL].[ 2011-10-01].http://www.encepp.eu/standards_and_guidances/index.html.
|
| [23] | Kahn N F, Harrison S E, Rose P W. Validity of diagnostic coding within the general practice research database: a systematic review[J]. Br J Gen Pract, 2010, 60(572): e128.
|
| [24] | Gerhard T. Bias: considerations for research practice[J]. Am J Health Syst Pharm, 2008, 65(22): 2159.
|
| [25] | Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics[J]. Pharmacoepidemiol Drug Saf, 2006, 15 (5): 291.
|
